Johnson & Johnson (JNJ) Total Debt (2008 - 2026)
Johnson & Johnson (JNJ) total debt from Dec 28, 2008 to Mar 29, 2026. The current Johnson & Johnson (JNJ) total debt is $120B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Johnson & Johnson (JNJ) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +35.76% |
| 3 Years TTM | +11.79% |
| 5 Years TTM | +13.17% |
| 10 Years TTM | +12.14% |
| All Time TTM | +12.78% |
Annual Total Debt change of Johnson & Johnson (JNJ)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $118B | +8.33% |
| 2024 | $109B | +9.95% |
| 2023 | $99B | -10.66% |
| 2023 | $111B | +2.39% |
| 2022 | $108B | -3.24% |
| 2021 | $112B | +13.60% |
| 2019 | $98B | +5.42% |
| 2018 | $93B | -4.06% |
| 2017 | $97B | +37.23% |
| 2017 | $71B | +13.70% |
| 2016 | $62B | +2.73% |
| 2014 | $61B | +3.37% |
| 2013 | $59B | +3.73% |
| 2012 | $57B | -0.08% |
| 2012 | $57B | +22.09% |
| 2011 | $46B | +5.07% |
| 2010 | $44B | +3.99% |
| 2008 | $42B | N/A |
Comparison Johnson & Johnson (JNJ) total debt with competitors
Johnson & Johnson (JNJ) total debt is $119.71B.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -100.00% |
| NSRX | Nasus Pharma Ltd | $2.24M | -100.00% |
| MDCX | MDCorp | $6.00M | -99.99% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | -99.99% |
| AMRN | Amarin Corp | $196.35M | -99.84% |
| SCLX | Scilex Holding Company | $547.71M | -99.54% |
| BIIB | Biogen Inc | $10.83B | -90.95% |
| OGN | Organon & Company | $12.09B | -89.90% |
| GRFS | Grifols SA | $12.24B | -89.77% |
| SNY | Sanofi | $54.88B | -54.15% |
| GSK | GSK Plc | $59.93B | -49.94% |
| BMY | Bristol-Myers Squibb Company | $66.37B | -44.55% |
| AZN | Astrazeneca plc | $66.63B | -44.34% |
| NVS | Novartis AG | $79.61B | -33.50% |
| PFE | Pfizer Inc | $117.21B | -2.08% |
| NVO | Novo Nordisk | $356.16B | +197.52% |